All the Drug Class Drugs
Immunoglobulins. Human Normal Immunoglobulin 160 mg/ml. PFS: 1 x 2 cc, 5 cc. See lit.
Defic. defect. antibody synth., protracted
transitory hypogammaglobulem.,
proph. hepatit. A, measles or attenuat.
measles.
C/I: Severe thrombocytopen., other
coag. disords., isolated immunoglobulin
A (IgA) defic.
Immunoglobulins. Human Immunoglobulin 50mg/ml. VIAL: 20 ml, 50 ml, 100 ml, 200 ml. The dose & dose regimen is depend. on the indicat. for each pt. depend. on the clin. response. Pts. bdywt. may require adjust. in underweight /overweight pts. See lit.
Replac. ther. in adult., child.,adolesc. (0-18 years) in:
Prim. immunodefic. syndr. (PID) with impair. antibod. product.
Second. immunodeficiencies (SID) in pts. who suffer from severe or recur.infect., ineffect. antimicrob. tmt. and either proven specific antibod. fail. (PSAF)* or serum IgG level of <4 g/l.
* PSAF = fail. to mount at least a 2-fold rise in IgG antibody titre to pneumococcal
polysaccharide and polypeptide antigen vaccin.
Immunomodulation in adult., and child. and adolesc. (0-18 years) in:
ITP, in pts. at high risk of bleed. or prior to surgery to correct the platelet count.
Guillain Barré syndr.
Kawasaki dis. (in conjunct. with acetylsalicyl. a.; See Lit.
Chronic inflammat. demyelinate. poliradiculoneuropathy (CIDP).
Multifoc.motor neuropath. (MMN).
C/I: Hypersens.
Pts. with selective IgA defic. who develop. antibodies to IgA, as administering an IgA contain. product can result in anaphylaxis.
Immunoglobulins. Human Normal Immunoglobulin 100 g/l. VIAL (sol.for infus.): 10, 25, 50, 100, 200 ml.
Replacem. ther. in primary immunodefic., init. dose: 0.4-0.8 g/kg, thereafter 0.2-0.8 g/kg every 3-4 wks. to obtain IgG trough level of IgG of at least 6 g/l. Replacem. ther. in second. immunodefic.: 0.2-0.4 g/kg, every 3-4 wks. Prim. immune thrombocytop.: 0.8-1 g/kg on day 1, possibly rpt once within 3 days, or 0.4 g/kg/d for 2-5 d. Guillain Barré syndr.: 0.4 g/kg/d for 5 d (possible rpt of dosing in case of relapse). Kawasaki dis.: 2 g/kg should be admin. as a sgle. dose. Pts should receive concom. tmt with acetylsalicylic acid. CIDP Starting dose: 2 g/kg div. over 2 -5 consecutive d. Mainten. doses: 1 g/kg over 1-2 consecutive d every 3 wks. MMN starting dose: 2 g/kg given over 2-5 consecut. days. Mainten. dose: 1 g/kg every 2 to 4 wks or 2 g/kg every 4 to 8 wks. Replacem. ther. in adults, child. and adolesc. (0-18 years) in: Primary immunodefic. syndr. (PID) with impair. antibod. prod. Second. Immunodefic. (SID) in pts with sev. or recur. infect., ineffective antimicrob. tmt and either PSAF or serum IgG level of <4 g/l. Immunomodul. in adults, child. and adolesc. (0-18 years) in:Primary ITP, in pts at high risk of bleed. or prior to surg. to correct platelet count. Guillain Barré syndr. Kawasaki dis. (in conjunct. w/acetylsalicylic acid). Chronic inflamm. demyelin. polyradiculoneuropathy (CIDP). Multifocal motor neuropathy (MMN).
C/I: Hypersens. to the active subst. or to any of the excip. Pts. with selective IgA defic. who develop antibod. to IgA, as admin. of IgA-contain. product can result in anaphylax.
Immunoglobulins. Human Normal Immunoglobulin 50 mg/ml. VIAL (sol.for infus.): 20, 50, 100, 200 ml.
Replacem. ther. in primary immunodefic., init. dose: 0.4-0.8 g/kg, thereafter 0.2-0.8 g/kg every 3-4 wks. to obtain IgG trough level of IgG of at least 6 g/l. Replacem. ther. in second. immunodefic.: 0.2-0.4 g/kg, every 3-4 wks. Prim. immune thrombocytop.: 0.8-1 g/kg on day 1, possibly rpt once within 3 days, or 0.4 g/kg/d for 2-5 d. Guillain Barré syndr.: 0.4 g/kg/d for 5 d (possible rpt of dosing in case of relapse). Kawasaki dis.: 2 g/kg should be admin. as a sgle. dose. Pts should receive concom. tmt with acetylsalicylic acid. CIDP Starting dose: 2 g/kg div. over 2 -5 consecutive d. Mainten. doses: 1 g/kg over 1-2 consecutive d every 3 wks. MMN starting dose: 2 g/kg given over 2-5 consecut. days. Mainten. dose: 1 g/kg every 2 to 4 wks or 2 g/kg every 4 to 8 wks. Replacem. ther. in adults, child. and adolesc. (0-18 years) in: Primary immunodefic. syndr. (PID) with impair. antibod. prod. Second. Immunodefic. (SID) in pts with sev. or recur. infect., ineffective antimicrob. tmt and either PSAF or serum IgG level of <4 g/l. Immunomodul. in adults, child. and adolesc. (0-18 years) in:Primary ITP, in pts at high risk of bleed. or prior to surg. to correct platelet count. Guillain Barré syndr. Kawasaki dis. (in conjunct. w/acetylsalicylic acid). Chronic inflamm. demyelin. polyradiculoneuropathy (CIDP). Multifocal motor neuropathy (MMN).
C/I: Hypersens. to the active subst. or to any of the excip. Pts. with selective IgA defic. who develop antibod. to IgA, as admin. of IgA-contain. product can result in anaphylax.
Immunoglobulins. Human Normal Immunoglobulin 100 g/l. VIAL (sol. for I.V. infus.): 1 x 2.5 g/ml; 5
g/50 ml; 10 g/100 ml. Depend. on
indicat. See lit.
Replace. ther. in prim. immunodefic.
synds such congen.
agammaglobulinem., hypogammaglob
ulinem., common/severe variable
immunodefic; Wiskott-Aldrich syndr:
Myeloma/chronic lymphocytic leukem.
with severe second.
hypogammaglobulinem. and recurr.
infects. Child with congent. AIDS and
recurr. infects. Immunomodulat: ITP in
child, adults at high risk of bleed./prior to
surgical intervents. to correct platelet
count; Guillan-Barré syndr., Kawasaki
dis.; Allogeneic bone marrow transplant.
C/I: Hypersens.
Immunoglobulins. Rabbit Anti-Human Thymocyte Immunoglobulin 25 mg/vial. VIAL (+ SOLVENT): 1 x 25 mg + 5 ml
solv. I.V. infus. depends on the indic.,
the admin. regimen and comb. with
other immunosuppr. agents. See lit.
Prev. and tmt. of graft reject., tmt of acute
GvHD, hematol. tmt of aplastic anem.
C/I: Act. acute or chron. infec. which
would contraind. addition. immunosupp.
Hypersens. to rabbit proteins or any of
the excip.